Withdrawn from the market (business decision)
Lesinurad
ZURAMPIC
What it isURAT1 (and OAT4) inhibitor that increases renal uric acid excretion (uricosuric).
Why this oneAdd-on to a xanthine oxidase inhibitor for gout patients not reaching target serum urate on the XOI alone.
What limits itMust be taken with a xanthine oxidase inhibitor and adequate hydration because of renal risk, and it was withdrawn from the market in 2019.
⚠ BOXED WARNING
- Acute renal failure
Principal riskBoxed warning: risk of acute renal failure, more common when used without a xanthine oxidase inhibitor.
Classes and tags
Clinical profile
Mechanism of action: Lesinurad ballicule
